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Abstract
Brain tumors are the most common type of solid cancer in children. 
Approximately 20% of pediatric brain tumors originate from the brain 
stem, and most are comprised of gliomas. However, metastasis of brain 
stem gliomas along the neuraxis is rare. Brain stem primitive neuroecto-
dermal tumors (PNETs) are also rare and are prone to leptomeningeal 
metastasis. We describe here a 10-year-old girl with a pontine tumor. 
Initially, she was diagnosed with a glioma because of the clinical presen-
tation, but later pathology of a metastatic tumor in the spinal cord showed 
PNET. The tumor response to radiotherapy was poor and she died 6 
months after diagnosis. Since biopsy of brain stem tumors is not always 
feasible, diagnoses other than glioma should be considered if the patient’s 
clinical presentation is unusual. [Tzu Chi Med J 2010;22(1):54–57]
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Intrinsic brain stem tumors account for 10% of all 
pediatric brain tumors, most of which are gliomas. 
The majority (85%) are composed of high-grade fibril-
lary gliomas, which arise predominantly in the pons 
and less frequently in the medulla. Low-grade glio-
mas (15%) are focal tumors that usually arise in the 
medulla or midbrain [1]. Primitive neuroectodermal 
tumors (PNETs) are malignant embryonic tumors oc-
curring most commonly in the cerebellum of young 
individuals [2]. PNETs arising from the brain stem are 
rare and the prognosis is poor [1,2]. In addition, ini-
tial detection of brain stem PNETs is difficult. Most 
neuro-oncologists avoid performing biopsies in chil-
dren with pontine tumors because of the risk of 
brain stem herniation. In these situations, clinicians 
usually treat brain stem tumors according to their 
experience and imaging findings, without pathologi-
cal evidence.
We describe here a 10-year-old girl with a brain 
stem tumor. Initially, she was diagnosed with pontine 
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glioma because of the clinical presentation, but later 
pathology of a metastatic tumor in the spinal cord 
showed PNET.
2. Case report
A 10-year-old girl had been healthy before February 
2008, when she suffered from progressive right up-
per and lower limb weakness and right central facial 
palsy for 1 week. She had no fever, cough, rhinorrhea, 
headache, vomiting, or diarrhea. A hemogram showed 
no abnormal findings (white blood cell count, 7700/
μL; hemoglobin, 14.2 g/dL; platelets, 253,000/μL; 
C-reactive protein, < 0.5 mg/L). Brain computed tom-
ography (CT) showed focal bulging with slightly in-
creased density of the left side pons (Fig. 1). Brain 
magnetic resonance imaging (MRI) (Fig. 2) revealed a 
2.6 × 2.1 × 2 cm well-defined intra-axial lesion involv-
ing the anterior aspect of the bilateral pons. The le-
sion was hypointense on T1-weighted images without 
obvious enhancement and was hyperintense on T2-
weighted images. Brain stem glioma was diagnosed 
according to the imaging findings and clinical pres-
entation. The patient received radiotherapy with a 
total dose of 3000 cGy in 20 fractions combined with 
temozolomide (100 mg/day for 25 days). During ra-
diotherapy, only a mild headache and nausea were 
observed. Her right side weakness persisted and she 
underwent rehabilitation.
Three months later, the patient suffered from head-
aches, vomiting, and blurred vision. Bilateral lower 
limb weakness was also found. Follow-up brain MRI 
(Fig. 3) showed interval regression of the size of 
the pontine tumor with intratumoral bleeding, but 
there was an enhanced nodule over the anterior as-
pect of the cervical spinal cord at C3 and increased 
Fig. 1 — Brain computed tomography shows focal bulging 
of the left pontine region (arrow) with slight hyperdensity.
Fig. 2 — Brain magnetic resonance imaging shows a well-
defined 2.6 ´ 2.1 ´  2 cm intra-axial lesion in the anterior pons 
(arrow), with hyperintensity on T2-weighted imaging.
Fig. 3 — Brain magnetic resonance imaging shows an en-
hanced nodule over the anterior aspect (arrows) of the 
cervical spinal cord at the C3 level.
leptomeningeal contrast enhancement in the basal cis-
terns and cerebellar sulci, which strongly suggested 
tumor seeding in the cerebral spinal fluid pathway. 
Spinal MRI (Fig. 4) showed extensive cerebral spinal 
fluid tumor seeding involving the entire spinal col-
umn with multiple sites of spinal cord compression. 
A biopsy of the metastatic nodule in the sacral area 
was carried out because of this rare manifestation of 
brain stem glioma. The pathology showed PNET. Our 
initial diagnosis of brain stem glioma was changed to 
brain stem PNET with leptomeningeal metastasis.
The patient’s condition progressed, her conscious-
ness became disorientated, and follow-up brain CT 
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showed hydrocephalus; for this reason, her parents 
refused insertion of a ventriculoperitoneal shunt. 
She received only palliative radiotherapy of the 
brain and whole spine, but chemotherapy was not 
performed because of her unstable condition. One 
month later, the patient died due to cardiopulmo-
nary failure.
3. Discussion
The term PNET was first introduced by Hart and Earle 
in 1973 to describe tumors that are clinically defined 
by their aggressive behavior. PNETs are malignant 
embryonic tumors occurring most commonly in the 
cerebellum of young individuals [2]. Ten percent of 
central nervous system PNETs arise outside the cer-
ebellum, and there have only been a few case re-
ports of brain stem PNETs [1,3–5].
Zagzag et al retrospectively reviewed 146 pediat-
ric patients with brain stem tumors, among which 
PNET was histologically diagnosed in seven patients 
(4.8%). Two of these PNETs were located in the pons. 
The median age of the patients was 2.7 years (range, 
1.0–8.0 years) [1]. All seven patients relapsed and 
had progression at the primary site, and six had ad-
ditional documented leptomeningeal dissemination. 
Only two patients responded to therapy. The median 
survival was 7 months (range, 3–17). Other reports 
of brain stem PNETs include one series of four cases 
originating in the pons [3], another series of two 
cases in the medulla and two cases in the region of 
the third cranial nerve [4], and an additional report 
of two cases with brain stem PNETs [5].
Fig. 4 — Spinal magnetic resonance imaging shows ex-
tensive cerebral spinal fluid tumor seeding involving the 
entire spinal column with multiple sites of spinal cord 
compression (arrows).
For our patient, we considered the possibility of two 
coexistent primary tumors (brain stem glioma and 
spinal PNET). There have not been any other such 
case reports of these two coexisting primary tumors. 
Zagzag et al reviewed a patient in whom PNET was 
pathologically proven throughout the subarachnoid 
space, but the pontine tumor had the appearance of 
a low-grade glioma [1]. At autopsy, they found that 
the neoplasm in the pons represented a zone of ad-
vanced astrocytic differentiation of the PNET. Thus, a 
diagnosis of brain stem PNET with spinal cord metas-
tasis was more favored than two independent pri-
mary tumors. In addition, in our patient, the tumor 
in the spinal cord was of a metastatic pattern rather 
than a primary pattern, which also supported our 
diagnosis.
There are no definite clinical characteristics distin-
guishing brain stem glioma from PNET. In brain MRI, 
both tumors are mostly hypointense on T1-weighted 
images with/without enhancement and hyperintense 
on T2-weighted images. PNETs are prone to leptome-
ningeal metastasis (42–100%), which occurs less 
frequently in brain stem gliomas (5–30%) [6]. Patients 
with brain stem PNETs are thought to be younger and 
have a higher tendency to have hydrocephalus at di-
agnosis than patients with gliomas [2]. A definite di-
agnosis is still dependent on histological findings.
Treatment of PNET/medulloblastoma consists of 
radiotherapy and chemotherapy, which provide long-
term progression-free survival in over 50% of children 
with PNETs arising in the cerebellum. Never theless, 
the prognosis of PNET in the brain stem is much 
poorer than that of PNET in the cerebellum [7]. From 
previous reports, patients with brain stem PNETs have 
a poor response to radiotherapy and chemotherapy, 
and no survival past 18 months has been reported 
[8]. Our patient received temozolomide treatment. 
Although adult studies with larger cohorts have con-
firmed a high response to temozolomide for both 
low-grade and high-grade astrocytomas and other gli-
omas, overall pediatric data suggest that temozolo-
mide activity may be less robust in children. However, 
a complete response was noted in one patient with 
PNET/medulloblastoma [9], and thus further study 
into the use of temozolomide for treatment of chil-
dren with medulloblastoma and other PNETs may be 
warranted.
Fangusaro et al reported two patients with brain 
stem PNETs initially treated with induction chemo-
therapy, and then consolidative chemotherapy fol-
lowed by autologous hematopoietic cell rescue [8]. 
Both patients received craniospinal irradiation with a 
boost to the primary tumor after hematopoietic res-
cue and remained long-term survivors at 32 and 38 
months with stable disease.
In conclusion, although the most common brain 
stem tumor is glioma, PNET might be the primary 
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pathology of brain stem tumors with spinal metasta-
sis. Close follow-up and spinal cord surveys are man-
datory for diagnosis when initial pathology in the 
brain stem is not available.
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